TG Therapeutics Logo
US88322Q1085
A1JXW7
TGTX

TG Therapeutics

Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è 73,31 € (+19,98%). La mediana è 73,31 € (+19,98%).

Acquista
  11
Mantieni
  1
Vendi
  1

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • TG Therapeutics raises revenue outlook, BRIUMVI gains market share in RMS

    TG Therapeutics reports strong commercial growth of BRIUMVI in relapsing multiple sclerosis and raises its 2024 revenue guidance to $890–905 million; the company is targeting a $1 billion run rate by the end of Q4. BRIUMVI has captured more than one-third of the IV anti‑CD20 market, a simplified IV dosing regimen should ease use, and a sBLA is upcoming. A subcutaneous formulation showed about 60% bioavailability in Phase I and will be tested in Phase III against two dosing intervals; TG sees broad potential also in myasthenia gravis and treatment‑resistant schizophrenia. » Altro su de.investing.com


  • TG Therapeutics stock recovers despite earnings miss

    TG Therapeutics shares rose intraday by 5.9%, extending the recovery after the sharp sell-off following the Q2 results. The company reported EPS of $0.05 versus a consensus of about $0.44; the miss was due to higher manufacturing and operating costs, not weak revenue. Revenue increased in the second quarter to roughly $240 million (+70% YoY) and the full-year guide was raised to about $950 million; additionally, the completed enrollment of the phase-3 trial for subcutaneous BRIUMVI administration could be another catalyst. » Altro su de.investing.com


  • TG Therapeutics climbs after Briumvi outperforms expectations and positive subcutaneous data

    ClearBridge's Q2 investor letter named TG Therapeutics as a top contributor after its key drug Briumvi delivered greater-than-expected growth and positive clinical results for a subcutaneous formulation that could expand the addressable market. The stock has risen sharply over the past month and year, reflecting renewed investor interest in the company's commercial-stage multiple sclerosis franchise. » Altro su finance.yahoo.com


  • TG Therapeutics hits 52-week high at $57.40

    Shares of TG Therapeutics rose to a 52-week high of $57.40 and are up about 86% year-to-date, bringing market capitalization to $8.09 billion. InvestingPro currently rates the stock as undervalued compared with its fair value. For Q1 2026 the company missed EPS expectations ($0.12 vs. $0.28) and reported slightly lower revenue of $194.8 million. TG Therapeutics is simultaneously advancing clinical programs with Briumvi, including initiated Phase 2 studies in treatment‑resistant schizophrenia and myasthenia gravis, positive post‑hoc Phase 3 data, and a successful ENHANCE study endpoint demonstrating bioequivalence of a new single‑dose infusion regimen. » Altro su de.investing.com


  • TG Therapeutics reaches 52-week high at 54.04 USD

    Shares of TG Therapeutics rose to a 52-week high of 54.04 USD, giving the company a market capitalization of about 7.57 billion USD; the stock is up 72.76% year-to-date and gained 52.54% over the past year. Despite the share price increase, the company missed Q1 2026 estimates with EPS of 0.12 USD (expectation 0.28 USD) and revenue of 194.8 million USD (forecast 199.45 million USD). TG Therapeutics also reported progress with BRIUMVI: start of a phase-2 maintenance study in myasthenia gravis, positive phase-1 topline data and positive post-hoc results, and a successful ENHANCE bioequivalence study in multiple sclerosis. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, TG Therapeutics ha registrato ricavi pari a 229,48 Mln € e un utile netto di 48,97 Mln €
(EUR) settembre 2026
YoY
Ricavi 229,48 Mln 66,54%
Utile lordo 192,34 Mln 69,00%
Utile netto 48,97 Mln 85,30%
EBITDA 79,24 Mln 184,44%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
8,64 Mld €
Numero di azioni
151,15 Mln
Massimo/minimo a 52 settimane
61,96 € - 24,37 €
Dividendi No
Beta
1,81
Rapporto P/E
84,25
Rapporto PEG
-1,11
Rapporto P/B
15,44
Rapporto P/S
10,57

Profilo aziendale

TG Therapeutics, Inc., un'azienda biofarmaceutica in fase commerciale, si concentra sull'acquisizione, lo sviluppo e la commercializzazione di nuovi trattamenti per le neoplasie a cellule B e le malattie autoimmuni. I suoi candidati farmaci terapeutici includono Ublituximab, un anticorpo monoclonale glicoingegnerizzato in fase di studio per il trattamento del linfoma non-Hodgkin a cellule B, della leucemia linfatica cronica (CLL) e delle forme recidivanti di sclerosi multipla; e Umbralisib, un inibitore orale di PI3K-delta e CK1-epsilon per il trattamento della CLL, del linfoma della zona marginale e del linfoma follicolare. L'azienda sviluppa inoltre Cosibelimab, un anticorpo monoclonale umano del sottotipo IgG1 che si lega al ligando di morte programmata 1 (PD-L1) e ne blocca le interazioni con i recettori PD-1 e B7.1; TG-1701 è un inibitore di tirosin-chinasi di Bruton (BTK) assumibile per via orale e a legame covalente, che mostra selettività verso BTK rispetto a ibrutinib in screening di chinasi in vitro; e TG-1801, un anticorpo bispecifico anti-CD47 e anti-CD19. Inoltre, l'azienda dispone di vari programmi preclinici in licenza per BET, la chinasi-4 associata al recettore dell'interleuchina-1 e GITR; e accordi di collaborazione con Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated e Jubilant Biosys. La società ha alleanze strategiche con LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; e Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. è stata costituita nel 1993 e ha sede a New York, New York.

Nome
TG Therapeutics
CEO
Michael S. Weiss
Sede centrale Morrisville, ny
Stati Uniti
Sito web
Settore
Sanità
Industria
Biotecnologia
Quotazione in borsa
03/05/2010
Dipendenti 399

Simboli di borsa

Borsa Simbolo
NASDAQ
TGTX
London Stock Exchange
0VGI.L
Frankfurt
NKB2.F
Düsseldorf
NKB2.DU
London
0VGI.L
SIX
NKB2.SW
München
NKB2.MU
🍪

Parqet  usa i cookie. Scopri di più